Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction.
Lee MH
,
Choi BY
,
Cho YY
,
Lee SY
,
Huang Z
,
Kundu JK
,
Kim MO
,
Kim DJ
,
Bode AM
,
Surh YJ
,
Dong Z
.
???displayArticle.abstract???
The tumor suppressor protein p16(INK4a) is a member of the INK4 family of cyclin-dependent kinase (Cdk) inhibitors, which are involved in the regulation of the eukaryotic cell cycle. However, the mechanisms underlying the anti-proliferative effects of p16(INK4a) have not been fully elucidated. Using yeast two-hybrid screening, we identified the eukaryotic elongation factor (eEF)1A2 as a novel interacting partner of p16(INK4a). eEF1A2 is thought to function as an oncogene in cancers. The p16(INK4a) protein interacted with all but the D2 (250-327 aa) domain of eEF1A2. Ectopic expression of p16(INK4a) decreased the expression of eEF1A2 and inhibited cancer cell growth. Furthermore, suppression of protein synthesis by expression of p16(INK4a) ex vivo was verified by luciferase reporter activity. Microinjection of p16(INK4a) mRNA into the cytoplasm of Xenopus embryos suppressed the luciferase mRNA translation, whereas the combination of p16(INK4a) and morpholino-eEF1A2 resulted in a further reduction in translational activity. We conclude that the interaction of p16(INK4a) with eEF1A2, and subsequent downregulation of the expression and function of eEF1A2 is a novel mechanism explaining the anti-proliferative effects of p16(INK4a).
Amiri,
eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration.
2007, Pubmed
Amiri,
eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration.
2007,
Pubmed
Anand,
Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer.
2002,
Pubmed
Bilanges,
Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies.
2007,
Pubmed
Browne,
Regulation of peptide-chain elongation in mammalian cells.
2002,
Pubmed
Caldas,
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.
1994,
Pubmed
Chen,
A novel shape complementarity scoring function for protein-protein docking.
2003,
Pubmed
Chen,
ZDOCK: an initial-stage protein-docking algorithm.
2003,
Pubmed
Choi,
The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity.
2005,
Pubmed
Collins,
Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
2005,
Pubmed
Ejiri,
Moonlighting functions of polypeptide elongation factor 1: from actin bundling to zinc finger protein R1-associated nuclear localization.
2002,
Pubmed
Evangelou,
Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas.
2004,
Pubmed
Gali-Muhtasib,
Modulating cell cycle: current applications and prospects for future drug development.
2002,
Pubmed
Hartwell,
Cell cycle control and cancer.
1994,
Pubmed
Hartwell,
Cell cycle checkpoints, genomic integrity, and cancer.
1994,
Pubmed
Humphrey,
VMD: visual molecular dynamics.
1996,
Pubmed
Joseph,
Expression profile of eukaryotic translation factors in human cancer tissues and cell lines.
2004,
Pubmed
Kahns,
The elongation factor 1 A-2 isoform from rabbit: cloning of the cDNA and characterization of the protein.
1998,
Pubmed
Khalyfa,
Characterization of elongation factor-1A (eEF1A-1) and eEF1A-2/S1 protein expression in normal and wasted mice.
2001,
Pubmed
Knudsen,
Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha.
1993,
Pubmed
Krimpenfort,
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice.
2001,
Pubmed
Kulkarni,
Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer.
2007,
Pubmed
Lee,
Tissue-specific expression in mammalian brain, heart, and muscle of S1, a member of the elongation factor-1 alpha gene family.
1992,
Pubmed
Lee,
Differential expression of S1 and elongation factor-1 alpha during rat development.
1993,
Pubmed
Lee,
Cloning of human and mouse brain cDNAs coding for S1, the second member of the mammalian elongation factor-1 alpha gene family: analysis of a possible evolutionary pathway.
1994,
Pubmed
Lee,
Terminal differentiation-dependent alteration in the expression of translation elongation factor-1 alpha and its sister gene, S1, in neurons.
1995,
Pubmed
Lee,
eEF1A2 as a putative oncogene.
2009,
Pubmed
Li,
Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas.
2010,
Pubmed
Lund,
Assignment of human elongation factor 1alpha genes: EEF1A maps to chromosome 6q14 and EEF1A2 to 20q13.3.
1996,
Pubmed
Marles,
Protein-protein interaction affinity plays a crucial role in controlling the Sho1p-mediated signal transduction pathway in yeast.
2004,
Pubmed
Mintseris,
Integrating statistical pair potentials into protein complex prediction.
2007,
Pubmed
Moldave,
Eukaryotic protein synthesis.
1985,
Pubmed
Panasyuk,
A2 isoform of mammalian translation factor eEF1A displays increased tyrosine phosphorylation and ability to interact with different signalling molecules.
2008,
Pubmed
Pardee,
A restriction point for control of normal animal cell proliferation.
1974,
Pubmed
Pinke,
The prognostic significance of elongation factor eEF1A2 in ovarian cancer.
2008,
Pubmed
Richter,
The mechanism for increased protein synthesis during Xenopus oocyte maturation.
1982,
Pubmed
,
Xenbase
Ruas,
The p16INK4a/CDKN2A tumor suppressor and its relatives.
1998,
Pubmed
Ruggero,
Does the ribosome translate cancer?
2003,
Pubmed
Ruggero,
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis.
2004,
Pubmed
Sanges,
Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells.
2012,
Pubmed
Scaggiante,
Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression.
2012,
Pubmed
Serrano,
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
1993,
Pubmed
Sherr,
Parsing Ink4a/Arf: "pure" p16-null mice.
2001,
Pubmed
Sherr,
CDK inhibitors: positive and negative regulators of G1-phase progression.
1999,
Pubmed
Soares,
Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation.
2009,
Pubmed
Sonenberg,
Regulation of translation initiation in eukaryotes: mechanisms and biological targets.
2009,
Pubmed
Swanton,
Cell-cycle targeted therapies.
2004,
Pubmed
Tomlinson,
Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours.
2005,
Pubmed
,
Xenbase
White-Gilbertson,
The role of protein synthesis in cell cycling and cancer.
2009,
Pubmed
